Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Heparin Treatment to Reduce Transmission of SARS-CoV-2 Infection and COVID 19 Disease Among Household Contacts
NCT05204550Phase 3Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of heparin in coronavirus disease 2019 (COVID-19), sponsored by Murdoch Children's Research Institute. Started Jan 2023; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05204550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204550.